B6/lpr mouse strain is a well-known systemic lupus erythematosus murine model characterized by uncontrolled lymphoproliferation and autoantibody production. However, it displays a delayed and mild development of lupus nephritis (LN), which is not conducive to the research of the pathogenesis and therapeutic strategies of this condition. Our previous study demonstrated that activated lymphocyte-derived DNA (ALD-DNA) could induce high urine protein levels and severe glomerulonephritis (GN) in BALB/c mice. In the present study, we tried to remedy delayed urine protein production and mild GN in B6/lpr mice via ALD-DNA immunization. We found that urine protein levels were enhanced significantly in B6/lpr mice 4 weeks after ALD-DNA immunization compared with those in unactivated lymphocyte-derived (UnALD)-DNA-and phosphate-buffered saline (PBS)-treated controls. Moreover, more serious GN and glomerular immune complex were observed in ALD-DNA-immunized B6/ lpr mice. We further explored the mechanism, and found that ALD-DNA immunization promoted T helper type 17 (Th17) cell enrichment remarkably, which enhanced the proportion of autoantibody-secreting plasma cells and promoted the production of anti-dsDNA autoantibodies, leading to accelerated and aggravated LN. Our data demonstrated that ALD-DNA immunization could remedy delayed urine protein production and mild GN in B6/lpr mouse, which makes it more suitable for studies on the pathogenesis of and therapeutic strategies against LN.
Introduction
Systemic lupus erythematosus (SLE) is a complex and potentially deadly autoimmune disease characterized by autoantibody production and severe pathological damage, such as vasculitis, arthritis and glomerulonephritis (GN) [1] [2] [3] . Lupus nephritis (LN) is a serious manifestation and a major cause of morbidity in SLE patients [4, 5] . However, the mechanisms underlying LN pathogenesis remain unclear. Hence, the availability of appropriate animal models may shed light in exploring the pathogenesis and finding effective therapeutic strategies against LN. Currently, animal researches on SLE pathogenesis apply mainly to lupus-prone mice.
There are multiple SLE murine models of different genetic backgrounds that have diverse pathological mechanisms, such as (NZB/NZW) F 1 , MRL/lpr, B6/lpr, C3H/gld/ gld and BXSB mice [6, 7] . Among them, the B6/lpr strain is used widely as it shares the same genetic background as C57BL/6 with a large number of gene-manipulated mice. This strain is a classic spontaneous SLE murine model carrying mutated Fas genes [8] , which leads to the enrichment of autoreactive lymphocytes via impairing activationinduced cell death and subsequently causes pathological autoreactive immune responses [9] [10] [11] [12] [13] . B6/lpr mice can mimic human SLE in many ways, such as severe lymphoproliferation and production of multiple autoantibodies [8] . However, the strain has limitations in simulating human LN, a serious and lethal manifestation of SLE, as evidenced by delayed urine protein production and mild GN [14] [15] [16] [17] . Therefore, aggravating LN severity in B6/lpr will make this murine model more suitable and comprehensive for studies on the pathogenesis and therapeutic strategies of SLE.
Our previous study demonstrated that activated lymphocyte-derived DNA (ALD-DNA) immunization could induce high urine protein levels and severe nephritis in BALB/c mice [18] . As the genetic background influences the pathological mechanisms of lupus murine model significantly, we extended our research to a lupus murine model of another genetic background, C57BL/6, to make it more continuous and comparable. In this study, we tried to remedy the defect of B6/lpr mice in simulating human LN by ALD-DNA immunization and evaluated further the possible mechanisms.
Materials and methods

Mice
B6.MRL-Fas lpr (B6/lpr) mice and 6-8-week-old C57BL/6 mice were purchased from Nanjing Biomedical Research Institute of Nanjing University and housed in the specific pathogen free animal laboratory of Soochow University. All animal studies were carried out in the light of the regulations of the Care and Use of Laboratory Animals (Ministry of Health, China, 1998) and the guidelines of the Ethics Committee of Soochow University (2015027).
DNA preparation
ALD-DNA and UnALD-DNA were prepared with splenocytes isolated from 6-8-week-old C57BL/6 mice, as described previously [19] [20] [21] .
Animal immunization
B6.MRL-Fas lpr mice were divided into three groups and injected subcutaneously under the dorsal skin with 0Á2 ml of an emulsion containing ALD-DNA (30 lg/mouse) in phosphate-buffered saline (PBS) plus complete Freund's adjuvant (CFA; Sigma, St Louis, MO, USA). Mice treated with an equal volume of PBS or unactivated lymphocytederived (UnALD)-DNA (30 lg/mouse) plus CFA were used as controls. Two and 4 weeks later, mice were given two booster immunizations consisting of the same DNA with incomplete Freund's adjuvant (IFA; Sigma), as described previously [18] [19] [20] [21] [22] [23] . Serum and urine samples were collected every 2 weeks.
Flow cytometry
For surface staining, single-cell suspensions were prepared and labelled with specific antibodies against CD4, CD8, CD19, CD138 and B220 (BD Pharmingen, San Jose, CA, USA) for 30 min on ice. For intracellular staining, splenocytes from B6/lpr mice 14 weeks after the first immunization were stimulated with 50 ng/ml phorbol myristate acetate (Sigma-Aldrich, St Louis, MO, USA), 1 lg/ml ionomycin (Peprotech, London, UK) and 10 lg/ml brefeldin A (Biolegend, San Diego, CA, USA) for 6 h at 378C, 5% CO 2 .
Intracellular staining was performed with allophycocyanin (APC)-anti-mouse interleukin (IL)-17A and APC-antimouse retinoid-related orphan receptor gamma (RORgt) (BD Pharmingen) antibodies using a fixation/permeabilization kit (BD Pharmingen), according to the manufacturer's instructions. Samples were analysed using fluorescence activated cell sorter (FACS)Canto II (BD Biosciences, San Jose, CA, USA) and data were analysed using FlowJo version 6.0 software (Tree Star, Inc., Ashland, OR, USA).
Enzyme-linked immunosorbent assay (ELISA) measurement of serum anti-dsDNA antibody levels Serum anti-dsDNA antibodies were assessed following a previously described ELISA assay [19] [20] [21] . 
ELISA measurement of urine protein level
ELISA for serum cytokines
To assess serum IL-17 levels, ELISA assays were performed using relative ELISA Kits (eBioscience, San Diego, CA, USA), according to the manufacturer's specifications.
Pathological analysis
Kidneys were isolated and fixed in 4% paraformaldehyde (Sigma) and embedded in paraffin, as described previously [19] [20] [21] . Haematoxylin and eosin (H&E) and periodic acid-Schiff (PAS) staining were performed in accordance with the manufacturer's instructions and assessed by two pathologists blinded to the treatment and control groups. The kidney score of glomerulonephritis was determined on a semiquantitative scale ranging from 0 to 4: 0 5 no remarkable change; 1 5 a small increase of glomerular mesangium cells; 2 5 global cell infiltration in the mesangium; 3 5 glomerular lobular formation and basement membrane thickening; 4 5 glomerular crescent formation, sclerosis, atrophy and casts [23] . Immunofluorescence study of cryostat sections was used for immune complex deposition analysis in the glomerular. Sections were incubated with anti-mouse immunoglobulin (Ig)G-FITC antibody (Abcam, Cambridge, UK) or anti-mouse C3-FITC antibody (Abcam) for 30 min. Pictures were obtained on a Nikon SCLIPSS TE2000-S microscope (Nikon, Tokyo, Japan) equipped with ACT-1 software (Nikon).
Blockade of IL-17 in vivo
In-vivo neutralization of IL-17 was performed using a neutralizing antibody to IL-17, as described previously [23] . Briefly, groups of B6/lpr mice were injected intraperitoneal with 100 lg anti-IL-17 antibody (Biolegend) or isotype control antibody (Biolegend) 24 h before self-DNA (ALD-DNA) immunization and then were given consistently every 3 days.
Real-time polymerase chain reaction (PCR) analysis
Total RNA samples were extracted from splenocytes with Trizol reagent (Invitrogen, Carlsbad, CA, USA). The RNA was reverse transcribed into cDNA with the PrimeScript RT reagent kit (Takara, Dalien, China), according to the manufacturer's instructions. The transcript levels of RORgt, IL-17, IL-6, transforming growth factor (TGF)-b, IL-21, IL-23 and IL-1b were detected by real-time quantification using SYBR Green system (Invitrogen) on the realplex Mastercycler (Eppendorf, Hamburg, Germany). To normalize the gene expression levels, housekeeping gene actin was analysed. All samples were analysed in duplicate.
Statistical analysis
Quantitative data are displayed as means 6 standard error of the mean (s.e.m.) of three independent experiments. All comparisons were performed using one-way analysis of variance (ANOVA) followed by Tukey's test. The statistical significance level was showed as *P < 0Á05, **P < 0Á01 and ***P < 0Á001. All statistical analyses were performed by using Graphpad Prism version 5 statistical software.
Results
ALD-DNA immunization accelerated and aggravated lupus nephritis in lupus-prone (B6/lpr) mice
Mice were immunized with ALD-DNA, UnALD-DNA and PBS in Freund's adjuvant, and then urine protein levels and kidney pathology were determined. We found that in B6/ lpr mice, urine protein levels were enhanced significantly 4 weeks after ALD-DNA immunization and increased continuously as time went by compared with UnALD-DNAand PBS-treated controls (Fig. 1a) . Furthermore, kidney pathological analysis and immunofluorescence assay showed more severe GN and glomerular C3 and IgG deposition after ALD-DNA immunization compared with controls ( Fig. 1b-d) . Moreover, remarkably increased serum IgG1 and IgG2b antibodies against dsDNA were found in ALD-DNA-immunized B6/lpr mice (Fig. 1e) . These results demonstrated that ALD-DNA immunization could accelerate and aggravate LN in B6/lpr mice.
ALD-DNA immunization promoted T helper type 17 (Th17) cell enrichment in B6/lpr mice, which greatly accelerated and aggravated LN
We found previously that ALD-DNA immunization could enhance serum IL-17 significantly, which aggravated LN in BALB/c mice [23] . In the present study, we also found that serum IL-17 levels and splenic Th17 cell proportions were elevated significantly in ALD-DNA-immunized B6/lpr mice (Fig. 2a,c,d ). Moreover, serum IL-17 levels and splenic Th17 cell proportions were correlated positively with urine protein levels and kidney pathology score (Fig. 2b,e) . These findings suggested that aggravated LN by ALD-DNA immunization in B6/lpr mice might be attributed to the expanded Th17 cells. By blocking IL-17 with neutralizing antibody, urine protein levels and kidney pathology score were decreased remarkably in ALD-DNA-immunized B6/lpr mice (Fig.  3a-c) . Additionally, the glomerular IgG and complement C3 deposition was also decreased (Fig. 3d) . Moreover, we found that blockade of IL-17 resulted in decreased serum IgG1 and IgG2b antibodies against dsDNA in ALD-DNAimmunized B6/lpr mice (Fig. 3e) . These results indicated that ALD-DNA could promote Th17 cell enrichment, which contributed greatly to the pathogenesis of LN in B6/ lpr mice.
ALD-DNA immunization enhanced the expression of Th17 differentiation-related transcription factor and cytokines in B6/lpr mice Th17 cell differentiation is regulated by transcription factor RORgt and a complex cytokine network, such as IL-6, IL-21, IL-23 and IL-1b [24] [25] [26] [27] . In this study, the splenic expression of IL-6, IL-21, IL-23 and IL-1b was increased significantly in ALD-DNA-immunized mice (Fig. 4d) . Accordingly, the percentage and number of CD4
1 RORgt
1
T cells were increased significantly compared with the control groups (Fig. 4a,b) . Moreover, the splenic expression of RORgt and IL-17 was increased significantly in ALD-DNAimmunized mice (Fig. 4c) . These results indicated that ALD-DNA immunization could promote Th17 cell differentiation during LN development in B6/lpr mice.
Expanded Th17 cells promoted anti-dsDNA autoantibody production by increasing B220 1 CD138
1 plasma cells in ALD-DNA-immunized B6/lpr mice Previous studies have shown that Th17 cells can promote anti-dsDNA antibody production [23] . In the present study, the concentration, titre and avidity index were increased significantly in ALD-DNA-immunized mice (Fig.  5a-c) . As shown in Fig. 5e ,f, splenic plasma cells were remarkably enriched in ALD-DNA-immunized mice. Interestingly, the high levels of anti-dsDNA antibodies and the proportion of splenic B220 1 CD138 1 plasma cells were correlated positively with the increased percentage of splenic Th17 cells (Fig. 5d,g ). Blocking IL-17 consistently could decrease significantly the concentration, titre and avidity index of anti-dsDNA autoantibodies and the percentage and number of B220 1 CD138 1 plasma cells in ALD-DNAimmunized mice (Fig. 6a-e) . These findings demonstrated strongly that ALD-DNA-induced expanded Th17 cells promoted the production of anti-dsDNA autoantibodies by increasing plasma cell proportions in B6/lpr mice. High anti-dsDNA autoantibody levels have been proved to be a significant feature of SLE and are associated closely with disease severity [28] . As shown in Fig. 6f ,g, the serum anti-dsDNA antibody levels were correlated positively with protein urine levels and kidney damage in ALD-DNAimmunized B6/lpr mice, which further accounted for the aggravation of LN in ALD-DNA-immunized B6/lpr mice. Data represent the means 6 standard error of the mean (s.e.m.) for five mice in each group (*P < 0Á05; **P < 0Á01; ***P < 0Á001).
Discussion
Murine models play a significant role in finding effective therapeutic drugs and exploring the pathogenesis of SLE. There are numerous SLE murine models of different genetic backgrounds, such as (NZB/NZW) F 1 , MRL/lpr, B6/lpr, C3H/gld/gld and BXSB mice [6, 7] . MRL/lpr mice, which develop severe early-onset autoimmune disease characterized by massive lymphadenopathy, abundant circulating autoantibodies and fetal glomerulonephritis, were first derived from the 12th generation of complex crosses among strains LG, AKR, C3H and C57BL/6 by Murphy and Roths [8, 29] . The MRL/lpr strain is homozygous for the lymphoproliferation spontaneous mutation and develops a severe kidney disease at 4-7 months of age [16] . However, onset and severity of symptoms associated with the lpr allele are strain-dependent [16] . Although lpr mice with the C57BL/6 background (B6/lpr) develop an autoimmune disease characterized by uncontrolled lymphoproliferation and multiple autoantibody production [11, 30] , previous studies have reported that B6/lpr mice display delayed and minimal LN [14] [15] [16] 31] . The B6/ lpr strain is not an optimal murine model for studies on LN. Therefore, accelerating and aggravating LN in the B6/ lpr mouse strain will make it more suitable for studies on the pathogenesis and therapeutic strategies of SLE.
Our previous study demonstrated that ALD-DNA immunization could induce severe renal damage in BALB/c mice [18] . Murine models of different genetic backgrounds proportion and urine protein, kidney pathology score was analysed in B6/lpr mice. Data represent the means 6 standard error of the mean (s.e.m.) for five mice in each group (*P < 0Á05; **P < 0Á01; ***P < 0Á001). have diverse pathological mechanisms and therapeutic targets. For example, the Toll-like receptor (TLR)-7 signal pathway contributes greatly to the pathogenesis of autoimmune responses in BXSB mice [32, 33] , but Fas signalling deficiency causes an autoimmune disorder in MRL/lpr mice [29] .
In order to make our research more continuous and comparable, we tried to remedy the defect of B6/lpr mice in simulating human LN by ALD-DNA immunization. ALD-DNA-immunized B6/lpr mice developed significantly higher urine protein levels and more severe glomerulonephritis and immune complex deposition compared with UnALD-DNA-and PBS-treated controls (Fig. 1) .
Our previous study has demonstrated that CD4 1 T cells play a crucial role in anti-dsDNA antibody production induced by ALD-DNA [22] . Upon stimulation, naive CD4 1 T cells can differentiate into different kinds of T helper cells, such as Th1, Th2, Th17, Th9, Th22 and regulatory T cells (T reg ) [34] . Previous research proved that Th17 cells play a significant role in mediating organ damage in both early and long-standing stages of SLE [35] [36] [37] . In B6/ lpr mice, ALD-DNA promoted Th17 cell enrichment, which was correlated closely and positively with the severity of LN (Fig. 2c-e) .
As mentioned in previous researches, RORgt is sufficient to decide IL-17 expression and is the effector transcription factor that establishes the Th17 differentiation lineage [34, 38] . Importantly, RORgt expression was increased dramatically in splenic CD4
1 T cells of ALD-DNAimmunized mice (Fig. 4a,b) . The differentiation of Th17 cells requires the presence of a complex cytokine network, such as IL-6, IL-21, IL-23, IL-1b and TGF-b [25] [26] [27] 39, 40] .
In the present study, the splenic expression of IL-6, IL-21, IL-23 and IL-1b was increased significantly in ALD-DNAimmunized mice (Fig. 4d) . As mentioned in a previous study, Th17 differentiation can occur in the absence of TGF-b signalling [41] . In our research, no notable increase in TG-Fb expression was found (data not shown). B cells can differentiate into plasma cells, which contribute to autoimmune response and lead to LN development via producing autoantibodies [42] [43] [44] [45] [46] . In the present study, ALD-DNA-induced expanded Th17 cells could promote the enrichment of B220 1 CD138 1 plasma cells and production of anti-dsDNA autoantibodies, leading to accelerated and aggravated LN (Fig. 5) .
Recent evidence has suggested that IL-17 is an important player in B cell differentiation. Hsu et al. [47] found that IL-17 down-modulates the chemotactic response of mouse B cells to the C-X-C motif chemokine 12 (CXCL12), thereby leading to their prolonged retention in the germinal centre. As Doreau et al. [48] have mentioned, IL-17 can promote B cell survival, proliferation and differentiation 
CD138
1 ) in B6/lpr mice. (g) The correlation between the splenic Th17 cell proportion and the proportion of splenic plasma cells was analysed in B6/lpr mice. Data represent the means 6 standard error of the mean (s.e.m.) for five mice in each group (*P < 0Á05; **P < 0Á01; ***P < 0Á001). The correlation between anti-dsDNA autoantibody level and the kidney pathology score was analysed in B6/lpr mice. Data represent the means 6 standard error of the mean (s.e.m.) for five mice in each group (*P < 0Á05; **P < 0Á01; ***P < 0Á001). into plasma cells via acting in synergy with B cell-activating factor, which is mediated mainly through nuclear factor kappa B (NF-jB)-regulated transcription factor Twist family BHLH transcription factor 1 (Twist-1).
Anti-dsDNA autoantibodies play a significant role in LN development [49] . Various histopathological patterns observed in SLE patients are a result of anti-dsDNA autoantibody deposition in distinct locations in the glomerulus [50] . In the present study, we found that Th17 cells promoted the production of anti-dsDNA autoantibodies by increasing plasma cell populations in B6/lpr mice. Moreover, anti-dsDNA autoantibody production was correlated closely and positively with the severity of LN (Fig. 6 ).
In conclusion, ALD-DNA immunization could optimize lupus-prone B6/lpr mice by remedying its defect in simulating LN. ALD-DNA immunization promoted Th17 cell enrichment, which enhanced the autoantibody-secreting plasma cells and promoted the production of anti-dsDNA autoantibodies, leading to accelerated and aggravated LN. Our study indicated that ALD-DNA immunization is a new approach to modify the B6/lpr strain and makes it a more suitable SLE murine model for studies on the pathogenesis of and therapeutic strategies against LN, and elucidates further the onset mechanism.
